XTL Biopharmaceuticals Ltd. announced that it received notification from Mr. David Kestenbaum, the company's Chief Financial Officer, of his desire to cease his services as the company's CFO and pursue other opportunities. Mr. Kestenbaum will continue working during his notice period and his successor will be announced in due course.